New Findings from AASLD Showcase Elafibranor’s Impact on PBC

The latest findings from the American Association for the Study of Liver Diseases (AASLD) have revealed promising advancements in the treatment of primary biliary cholangitis (PBC) through the use of elafibranor. This news was shared during the recent Liver Meeting, where researchers presented long-term data from the phase 3 ELATIVE trial’s open-label extension.

Held in a conference center noted for its chilly temperatures, the event offered a much-needed refuge on the third floor, where attendees found warmth and comfort. Despite the cold conditions, the atmosphere was lively as participants engaged with the latest research.

Significant Trial Results for Elafibranor

The ELATIVE trial focused on the long-term effects of elafibranor, a treatment that received accelerated approval from the Food and Drug Administration (FDA) in June 2024 as a second-line therapy for PBC. The chronic liver disease is marked by inflammation and damage to the bile ducts, leading to various health complications.

In this extension trial, over three years of treatment involving 115 patients demonstrated sustained improvements in key biomarkers indicative of bile flow. Most participants also experienced stabilization in fibrosis markers, indicating a potential to slow disease progression. Notably, improvements in symptoms such as moderate-to-severe fatigue and itching persisted throughout the treatment period.

Importantly, no new safety concerns emerged during the trial, and further investigations are planned as the ELATIVE extension continues. These results suggest that elafibranor may play a critical role in managing PBC, offering hope to those affected by this challenging condition.

As the AASLD conference concludes, attendees depart with not only new knowledge but also optimism for the future of liver disease treatment. The insights gained from the ELATIVE trial could significantly alter therapeutic strategies and improve patient outcomes in the months and years to come.